Image

Global 5-Alpha Reductase Deficiency Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global 5-Alpha Reductase Deficiency Market, By Diagnosis (Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Others), Treatment (Surgery, Hormone Replacement Therapy, Others), Age of Onset (Childhood, Neonatal, Infancy, Adolescent), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

5-Alpha Reductase Deficiency Market

Market Analysis and Size                              

5-alpha reductase deficiency is a rare sex development disorder (DSD) characterized by incomplete intrauterine masculinization, ranging from a female genitalia with a blind vaginal pouch to a fully male phenotype with pseudovaginal posterior hypospadias and micropenis, and caused by a defect in metabolizing testosterone to dihydrotestosterone. Mutations in the SRD5A2-gene (2p23.1) allow the steroid 5 alpha-reductase type 2 enzyme, which converts testosterone into DHT in the external genitalia, to work poorly or not at all, resulting in the condition. As a result, despite high amounts of testosterone in the blood, male differentiation does not occur throughout foetal development. The levels of residual enzymatic function determine the manifestations at birth.

Data Bridge Market Research analyses that the 5-alpha reductase deficiency market was valued at USD 1.08 billion in 2021 and is expected to reach USD 1.83 billion by 2029, registering a CAGR of 6.80% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Diagnosis (Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Others), Treatment (Surgery, Hormone Replacement Therapy, Others), Age of Onset (Childhood, Neonatal, Infancy, Adolescent), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Alma Lasers (Israel), LUTRONIC (South Korea), ThermiGen, LLC. (US), Viveve Solutions (US), Venus Concept (Canada), Fotona (Slovenia), Almirall, S.A (Spain), Hologic, Inc. (US), Allergan (Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Merck KGaA (Germany), Novo Nordisk A/S (Denmark), Abbott (US)

 

Market Opportunities

 

  • Increase in the number of research and development activities

Market Definition

 5-alpha-reductase deficiency is a congenital disease that affects male sexual development. It is classified as a sexual differentiation disorder, sometimes known as an intersex condition. This disorder causes children to appear female at birth, but they will grow male genitalia during adolescence. The main concern for male patients is to maintain the testis for later hormone production. After diagnosis, topical DHT cream in the pubic area can be applied neonatally, at least during mini puberty. Hypospadias surgery should be done between the ages of 6 and 18 months. For patients who were raised as females, surgical correction of the external genitalia, early removal of gonadal tissue to prevent masculinization before puberty, clitoral reduction, and cyclic hormonal therapy at puberty to prevent the development of secondary sexual characteristics are all options.

5-Alpha Reductase Deficiency Market Dynamics

Drivers

  • Rise in the number of cases of 5-alpha reductase deficiency

The surging number of cases of 5-alpha reductase deficiency is a major factor driving the market's growth rate during the forecast period of 2022-2029. Ambiguous genitalia is an extremely unusual condition in infants, occurring in 1 out of every 4500 live births. Even with recent technological improvements such as genetic testing, hormone assays, and karyotyping, only 20 to 40% of the time these youngsters can be diagnosed. One of the most common reasons of ambiguous genitalia in children is a lack of the enzyme 5 alpha-reductase type 2 (5alpha-RD2).

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of 5-alpha reductase deficiency market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of 5-alpha reductase deficiency market. Along with this, favourable reimbursement policies will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the 5-alpha reductase deficiency market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the 5-alpha reductase deficiency market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the 5-alpha reductase deficiency market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This 5-alpha reductase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the 5-alpha reductase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

In white persons, the condition is quite infrequent. The Dominican Republic has a high prevalence of 5 alpha-RD2 deficiency due to a large number of consanguineous marriages; the first recorded case of 5 alpha-RD2 deficiency was also from the same island. This disease is also found in southern Lebanon and Papua New Guinea and the Caribbean.

5-alpha reductase deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global 5-Alpha Reductase Deficiency Market Scope

The 5-alpha reductase deficiency market is segmented on the basis of diagnosis, treatment, age of onset, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

  • Chromosome Analysis
  • Gene Sequencing
  • Hormone Tests
  • Imaging Tests
  • Ultrasound
  • Others
  • Genetic Screening
  • Others

Treatment

Age of Onset

  • Childhood
  • Neonatal
  • Infancy
  • Adolescent

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

5-Alpha Reductase Deficiency Market Regional Analysis/Insights

The 5-alpha reductase deficiency market is analysed and market size insights and trends are provided by country, diagnosis, treatment, age of onset, end-users and distribution channel as referenced above.

The countries covered in the 5-alpha reductase deficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the 5-alpha reductase deficiency market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of 5-alpha reductase deficiency and rising healthcare expenditure will further propel the 'market's growth rate in this region. Additionally, growing presence of major key players will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the 'market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and 5-Alpha Reductase Deficiency Market Share Analysis

The 5-alpha reductase deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to 5-alpha reductase deficiency market.

Some of the major players operating in the 5-alpha reductase deficiency market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • Abbott (US)
  • Merck KGaA (Germany)
  • Alma Lasers (Israel)
  • LUTRONIC (South Korea)
  • ThermiGen, LLC. (US)
  • Viveve Solutions (US)
  • Venus Concept (Canada)
  • Fotona (Slovenia)
  • Almirall, S.A (Spain)
  • Hologic, Inc. (US)
  • Novo Nordisk A/S (Denmark)

Research Methodology: Global 5-Alpha Reductase Deficiency Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

5-Alpha Reductase Deficiency Market grow at a CAGR of 6.80% by 2029
5-Alpha Reductase Deficiency Market grow at a CAGR of 6.80% by 2029
The major players operating in the 5-alpha reductase deficiency market are: F. Hoffmann-La Roche Ltd. (Switzerland) Mylan N.V. (US) Sanofi (France) Pfizer Inc. (US) GlaxoSmithKline plc (UK) Novartis AG (Switzerland) Bayer AG (Germany) Eli Lilly and Company (US) Merck & Co., Inc. (US) Allergan (Ireland) Abbott (US) Merck KGaA (Germany) Alma Lasers (Israel) LUTRONIC (South Korea) ThermiGen, LLC. (US) Viveve Solutions (US) Venus Concept (Canada) Fotona (Slovenia) Almirall, S.A (Spain) Hologic, Inc. (US) Novo Nordisk A/S (Denmark).
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the 'market's growth rate in this region.